Two drugmakers say their vaccines, which include J&J’s one-dose candidate, are effective against new coronavirus variants, while AstraZeneca’s vaccine is now approved for adults across the European Union.
Researchers urge priority vaccination for individuals with diabetes … AstraZeneca vaccine approval iffy in U.S. with current data, OWS scientist says … WHO trial finds no benefit of 4 drugs for hospitalized COVID patients … COVID antiviral pill trials move forward, long-term care component added … Interactive tool helps find your place in line for…
The vaccine was most protective — at 90% efficacy — when participants received an initial half dose and then a full dose a month apart, the U.K. drugmaker says.
The experimental vaccine was safe and well-tolerated among all 560 trial participants, including adults aged 70 and older, the company said Thursday.
The experimental vaccine also reduced the risk of adverse events in older study participants, the drugmaker reports.
The federal government is planning to stockpile COVID-19 antibody drugs in an effort to ensure treatment availability while the country awaits a vaccine.
AstraZeneca COVID vaccine trial on hold in U.S. despite resuming elsewhere … Collapsed lung a complication of COVID-19; specialist care needed for older men … Pfizer, BioNTech enlarge late-stage coronavirus vaccine trial … Diet may protect former smokers against rheumatoid arthritis … AHCA/NCAL video celebrates recoveries from COVID-19 in long-term care
A vaccine participant in the United Kingdom developed a rare inflammatory disease, causing AstraZeneca to pause its Phase 3 COVID-19 trials.
First federal count: more than 25,000 coronavirus deaths in nursing homes … AstraZeneca’s heart drug for high-risk patients receives FDA approval … Senior living operator balances safety, quality of life in the COVID-19 era … U.S. hospitals slash hydroxychloroquine use after studies reveal risks, suggest ineffectiveness … CDC: U.S. COVID-19 transmission likely began in January
AstraZeneca is not entitled to more exclusivity with its antischizophrenic medication, an appeals court agreed last week. The company had claimed its drug, Seroquel, deserved another three-year extension under the Food Drug and Cosmetic Act.
